Video
Dr. Campbell on promise of infigratinib in FGFR3 mutation–positive UTUC
Author(s):
“Several of these patients were able to undergo surgery that spared them the need to remove their ureter and their kidney,” says Matthew T. Campbell, MD.
Matthew T. Campbell, MD, discusses the abstract, “Interim Results From a Phase 1b Clinical Trial Evaluating Tolerability and Activity of FGFR Inhibition in Localized Upper Tract Urothelial Carcinoma (UTUC),” which he presented at the 2022 AUA Annual Meeting (abstract LBA01-10). The interim study data showed that infigratinib demonstrated strongactivity in patients with localized UTUC harboring FGFR3 mutations. Campbell is an assistant professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
